Possible Roles of the Xenobiotic Transporter P-glycoproteins Encoded by the MDR1 3435 C>T Gene Polymorphism in Differentiated Thyroid Cancers

Semra Ozdemir1*, Ahmet Uludag1, Fatma Silan1, Sinem Yalcintepe Atik1, Bulent Turgut2, Ozturk Ozdemir1,2

Abstract

Background: P-glycoprotein (Pgp), encoded by the multidrug resistance 1 (MDR1) gene, is an efflux transporter which plays an important role in pharmacokinetics. The current preliminary study was designed to determine associations between a germline polymorphism in the MDR1 gene with differentiated thyroid carcinoma (DTC).

Materials and Methods: In the current case-control study, 60 differentiated thyroid cancers (DTC)- 45 papillary TC (PTC), 9 follicular TC (FTC) and 6 well-differentiated tumors of uncertain malignant potential (WDT-UMP) were examined. Results were compared to a healthy control group (n=58) from the same population. Genomic DNA was extracted from peripheral blood with EDTA and the target gene was genotyped by real-time PCR.

Results: Carriers of the variant allele of MDR1 exon 26 polymorphism were at 2.8-fold higher risk of DTC than the control group (odds ratio [OR]: 0.3805, 95% confidence interval [CI]: 0.1597-0.9065 (p> 0.046).

Conclusions: Presented results suggest that the MDR1 3435TT genotype might influence risk of development of DTC and that the CC genotype might be linked to a poor prognosis. Large-scale studies are now needed to validate this association.

Keywords: Differentiated thyroid carcinoma - MDR1 gene - increased T allele frequency in codon C3435T

Asian Pacific J Cancer Prev, 14 (5), 3213-3217

Introduction

The differentiated thyroid cancer (DTC), the most common type of all thyroid cancers accounts for >90%. It widely occurs in papillary and follicular types and its incidence has been increasing (Amrosini et al., 2011; Mondal et al., 2011; Sedov and Khmelevskaia, 2011; Caglar et al., 2012; Quan et al., 2012; Lerch and Richter, 2012). Early and/or late stage types of DTC may initiate by point mutations in different proto-oncogenes such as; RET, B-RAF, NTRK1 and K-RAS (Moura et al., 2011; Namba et al., 2003), functional gene inactivation that is triggered by point mutations (Weier et al., 2009; Moses et al., 2010) and epigenetic alterations in some target genes (Sharma et al., 2010; Lu et al., 2011). Despite remarkable advances have occurred in recent years in understanding the etiopathogenesis of thyroid cancer, the exact molecular etiological mechanism still remain unclear. Papillary and follicular carcinomas commonly occur in one or more cervical lymph nodes that refer to as follicular cell-derived DTC of high percentage of all thyroid carcinomas. In general, DTC prognosis is easy for some patients but in a considerable number of patients, approximately 30%, have recurrent disease. The appropriate initial treatment which includes total thyroidectomy and radioiodine remnant ablation therapy with I-131 after thyroidectomy is a common application in patients with DTC (Kingpetch et al., 2011; Nixon et al., 2011; Zakani et al., 2011; Deandreis et al., 2012; Manduz et al., 2011).

It is well known that the toxic endogenous substances such as; drugs and xenobiotics are playing a crucial role in the development of cancer in different tissues. The P-glycoprotein (Pgp) is a ATP-dependent efflux transporter protein that is encoded by the multidrug resistance gene MDR1 (ABCB1) and is expressed in many normal tissues such as; biliary ductiles, pancreas, kidneys, adrenal glands, choroid plexus of the brain, placenta and white blood cells regarding its multiple physiologic function. Functional protein plays an important role in transporting exogenous-endogenous substrates and xenobiotics, mediating cancer drug resistance across the blood-brain barrier. It is suggested that this transporter acts as a protective barrier to keep toxins out of the cell tissue and organs. The single nucleotide polymorphisms (SNPs) in MDR1 gene may restrict intestinal absorption of various carcinogens, including heterocyclic amines
Semra Ozdemir et al

(HCA) and polycyclic aromatic hydrocarbons (PAH) and may promote gastrointestinal carcinogenesis, affecting angiogenesis, apoptosis, and invasiveness as claimed by Andersen et al. (2009). Owing to the fact that it controls the efflux of toxic compounds, the Pgp transporter takes crucial role in the process of detoxification and elimination of xenobiotics which in turn is related to cancer risk (Andersen et al., 2009).

By the current case-control study we wished to explore the possible role of the xenobiotic transporter P-glycoprotein polymorphism (encoded by the MDR1 gene) that is also known as the transport dietary carcinogen in the susceptibility of differentiated thyroid cancer.

Materials and Methods

Patients, clinical diagnosis and laboratory assessment

In a total of 60 thyroid cancer patients; 45 papillary thyroid cancer (PTC), 9 follicular thyroid cancer (FTC), 6 well-differentiated tumors of uncertain malignant potential (WDT-UMP) of 11 male (18.3%), 49 female (81.7%) and mean age-min-max: 55.25±3.22(28-75) were included in the current results. The PTC patients were include; 19 (42.2%) cases of conventional, 15 (33.3%) diffuse sclerosing variant, 7 (15.5%) follicular and 4 (8.8%) oncocytic subtypes of PTC patients. The current FTC patients were include; 7 (77.7%) of conventional and 2 (32.3%) of Hurtle cell carcinomas histopathologically according to the WHO classification. Patients were genotyped for MDR1 C3435T SNP and compared to the healthy controls that are excluded from any familial cancer history. Results were compared to the 58 healthy control individuals from the same population that published in our previous case-control study (18). The volunteer individuals who has no any thyroid diseases were used as a control group cohort from the same population. There was no thyroid cancer history in those control cohort and their first degree relatives. The current study was performed in Departments of Nuclear Medicine and Medical Genetics of Cumhuriyet University Hospital between 2007-2009 years. All applications were approved and informed consent was obtained from all of the patients and control group individuals.

Mutation analysis

Blood samples with EDTA from 60 thyroid cancer patients that underwent total thyroidectomy were used in the current study. Total genomic DNA was extracted from peripheral blood samples from each individual by both automated Magna Pure Compact (Roche) and Invitrek kit extraction techniques (Invitrek®; Invisorb spin blood, Berlin, Germany) manually. Target MDR1 gene was genotyped by Real Time PCR, LightCycler 2.0 methods (Roche) for all patients. Briefly, LightCycler FastStart DNA Master HybProbes, master mix (water, PCR-grade, MgCl₂, stock solution, Primer mix, HybProbe mix) and DNA template were used for real-time amplification. The protocol consisted of a denaturation step of 30 seconds at 95°C; followed by amplification step of 45 cycles of 5 seconds at 95°C, 5 seconds at 55°C, and 8 seconds at 72°C; and melting curve analysis of 30 seconds at 95°C, followed by 2 minutes at 40°C, 0.1 second (continuous) at 80°C, cooling step of 30 seconds at 40°C. Software programme (LightCycler 2.0, Roche) was used for detection of the mutated and normal genotype profiles of target gene in the current DTC patients.

Statistical analysis

In current results the odds ratio and p-values were used to estimate the risk for C, T alleles frequency of codon 3435 SNP for MDR1 gene in DTC patients. The software SPSS for Windows version 12.0 was used to perform statistical analysis. Mutational variables were analyzed by using Fisher’s exact test. The Mann–Whitney U and chi-square tests were used to analyze differences between the patients and the controls. The estimate risk was examined by multivariate logistic regression analysis. Results were given as the mean (standard deviation [SD]).

Results

In the current case-control study it was aimed to find out the association between germ-line point mutations in MDR1 gene and thyroid carcinomas. By multiplex Real-time PCR technique, we evaluated common SNP 3435 C>T for MDR1 gene in DTC patients and results were compared to the healthy controls (Figure 1). The estimate risk was examined by multivariate logistic regression analysis. Statistically, the TT homozygous genotype of polymorphic 3435 C>T SNP codon was associated with a significance of 2.8 fold increase in risk for DTC patients in the current results.

Clinicopathologic data and follow-up knowledge

Peripheral blood-EDTA samples from healthy controls and DTC patients were examined for genotyping in the current study. In a total of 60 DTC patients [(49F (81.7%) and 11M (18.3%))] of 45 PTC (75%), 9 FTC (15%) and 6 UMP (10%) mean age 55.25±13.22 (28-75) were clinically diagnosed and treated. The subtypes and some clinical characteristics such as; mean age, sex distribution of patients were given in Table 1. The

Figure 1. Shows Melting Peak Profiles of Real Time – PCR for wild (A) and Mutated Genotypes for MDR1 3435 C>T SNPs in the Current DTC Patients. B: Homozygous Mutated TT Alleles, C: Heterozygous CT alleles
Table 1. Shows Some Clinical Characteristics of Age, Gender and Tumour Types of Current Patients with Differentiated Thyroid Carcinomas

<table>
<thead>
<tr>
<th>Clinical Characteristics</th>
<th>DTC Patients</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=60)</td>
<td>(n=58)</td>
<td></td>
</tr>
<tr>
<td>Tumour type</td>
<td>PTC</td>
<td>FTC</td>
</tr>
<tr>
<td>n(%)</td>
<td>45 (75%)</td>
<td>9 (15%)</td>
</tr>
<tr>
<td>Gender n (%)</td>
<td>F</td>
<td>49 (81.7)</td>
</tr>
<tr>
<td>M</td>
<td>11 (18.3)</td>
<td>38 (65.5)</td>
</tr>
<tr>
<td>The mean age±SD</td>
<td>55.25±3.22</td>
<td>58.8±11.6</td>
</tr>
<tr>
<td>(Min-Max)</td>
<td>(28-75)</td>
<td>(38-67)</td>
</tr>
</tbody>
</table>

Table 2. Mutation Distribution, Genotype, and Allele Frequency of Codon 3435 C>T SNP of the MDR1 Gene [P-glycoprotein, ATP-binding Cassette (ABCB1) Superfamily of Membrane Transporters] in the Current DTC Patients and Control Groups

<table>
<thead>
<tr>
<th>Gene</th>
<th>MDR1 (ABCB1)</th>
<th>Exon</th>
<th>26</th>
<th>SNP</th>
<th>Transition C&gt;T</th>
<th>Codon</th>
<th>3435</th>
</tr>
</thead>
</table>

Table 3. The Latest Literature Findings about Strong Association of T Allele Frequency of MDR1 Gene C>T SNP in Distinct Tumour Types in Human in Different Populations

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Population</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectal</td>
<td>The meta-analysis</td>
<td>^He et al, 2013</td>
</tr>
<tr>
<td>Colorectal</td>
<td>North German</td>
<td>^Campa et al, 2012</td>
</tr>
<tr>
<td>Breast</td>
<td>Canary Islands(Spain)</td>
<td>^Henríquez-Hernández, 2009</td>
</tr>
<tr>
<td>Gastric</td>
<td>Iranian</td>
<td>^Sabahi et al, 2010</td>
</tr>
<tr>
<td>Gastric</td>
<td>Chinese</td>
<td>^Li et al, 2011</td>
</tr>
<tr>
<td>Ovarian</td>
<td>Japan</td>
<td>^Nakajima et al, 2005</td>
</tr>
<tr>
<td>Lung</td>
<td>Turkish</td>
<td>^Dogu et al, 2012</td>
</tr>
<tr>
<td>Hepatic</td>
<td>Chinese</td>
<td>^Huang et al, 2012</td>
</tr>
</tbody>
</table>

^Significant: The status of T allele frequency for MDR1 C>T SNP
The MDR1 C3435T polymorphism in exon 26 has been extensively investigated in the variability in cancer risk and therapeutic outcome (Andersen et al., 2009; Jasim et al., 2011; Lu et al., 2011; Manduz et al., 2011). Lots of researchers claim that point mutation in MDR1 causes lower in vitro P-glycoprotein activity, changes substrate specificity, and alters expression due to the following factors: a lower mRNA stability, protein folding and altered ability of tissues to remove toxins and properly metabolize anticancer drugs. That might help explain the initiate and develop of different types of cancer, as well as design appropriate therapies based on the particular genetic composition of the tumors (Kroetz et al., 2003; He et al., 2010). The polymorphic homozygous (T/T) genotype of MDR1 gene showed a significant association with the incidence of gastric (Sabahi et al., 2010) and colorectal cancers (Andersen et al., 2009).

Pharmacogenomics and pharmacogenetics studies have revealed that mutated MDR1 gene is associated with alteration in P-gp expression and function and associated with higher risk of clinical conditions. Rao et al. (2010) have claimed that MDR1 TT genotype might influence the risk to develop an acute lymphoblastic leukemia (ALL) due to the lower activity of eliminating antileukemic drugs such as; anthracyclines, daunorubicin, vincristine, mitoxantrone that lead to lower intra cellular drug concentrations and a poor prognosis in ALL (Rao et al., 2010). Huang et al. (2011) have reported that P-glycoprotein that is encoded by mutated MDR1 gene may be implicated into the hematotoxicity of benzene. Subjects carrying MDR1 3435 T/T genotype may have a higher risk of benzene poisoning (Huang et al., 2011). Crouthamel et al. (2010) have reported a novel genetic variation of GT1292-3TG, (Cys431Leu) in MDR1 gene in leukemia patients by the accumulation of the intracellular doxorubicin, vinblastine, and paclitaxel (Crouthamel et al., 2010). P-glycoprotein, highly restricts the entry of ivermectin into the brain by an ATP-driven efflux mechanism at the blood-brain barrier. In dogs with a homozygous MDR1 TT mutation though, ivermectin accumulates in the brain and provokes severe signs of neurotoxicosis and even death (Geyer et al., 2009).

Recently, there are lots of crucial reports about MDR1 gene polymorphism and distinct human cancers in the literature (Li et al., 2001; Nakajima et al., 2005; Henriquez-Hernandez et al., 2009; Ni et al., 2011; Campa et al., 2012; Dogu et al., 2012; Qian et al., 2012; Huang et al., 2012; Sheng et al., 2012; Wang et al., 2012; He et al., 2013), (Table 3). We found that the functional SNP of MDR1 gene was associated with DTC risk in the Turkish population. The current preliminary results on MDR1 mutability on thyroid cancer are the first literature findings that showing mutation prevalence of the multidrug resistance MDR1 (ABCB1) gene in DTC.

In the current preliminary study it was aimed to find out the possible linkage between homozygous mutated (T/T alleles) MDR1 gene and DTC. Genomic DNA was extracted from peripheral blood and genotyped by Real Time PCR method. Presented results are the first report the genotype and allele frequency of polymorphic codon 3435 of MDR1 gene in Turkish DTC patients. Preliminary results of the current study showed that homozygous T allele in 3435 C>T codon in MDR1 gene may be associated with high risk of thyroid cancer and may play a pivotal role in the development of DTC in human. Despite some limitations, current results indicated that individuals with homozygous TT genotype had a 14.67% higher risk of having DTC. Furthermore, patients carrying both copies of the variant alleles (TT) showed 2.8 times increased risk of developing DTC than their control counterparts. By the presented case-control results it is possible to claim that the polymorphic xenobiotic transporter P-glycoprotein (encoded by the MDR1 gene) which is also known as the transport dietary carcinogen is associated with susceptibility of DTC.

In conclusion, the codon 3435 C>T transitional polymorphism in exon 26 of MDR1 gene was significantly associated with DTC risk in the current results. Results need to be supported by population based large–scale samples of representative DTC patients.

References


Geyer J, Gawrilova O, Petzinger E (2009). Brain penetration of ivermectin and selamectin in a common (encoded by the MDR1 gene) which is also known as the transport dietary carcinogen is associated with susceptibility of DTC.

In conclusion, the codon 3435 C>T transitional polymorphism in exon 26 of MDR1 gene was significantly associated with DTC risk in the current results. Results need to be supported by population based large–scale samples of representative DTC patients.

References


Geyer J, Gawrilova O, Petzinger E (2009). Brain penetration of ivermectin and selamectin in a common (encoded by the MDR1 gene) which is also known as the transport dietary carcinogen is associated with susceptibility of DTC.
29, 83-90.
gene transcription through p53 expression in
polymorphism and colorectal cancer risk: a meta-analysis
of case-control studies. Colorectal Dis, 15, 12-8.
Henriquez-Hernández LA, Murias-Rosales A, Hernández
MTTHFR, p53 and MDR1 as risk factors for breast cancer: a
case-control study. Oncol Rep, 22, 1425-33.
C3435T on peripheral white blood cell counts in workers
exposed to benzene. Zhonghua Lao Dong Wei Sheng ZhiYe Bing Za Zhi, 29, 20-3.
Huang C, Xu D, Xia Q, et al (2012). Reversal of P-glycoprotein-
mediated multidrug resistance of human hepatic cancer cells
by astragaloside II. J Pharm Pharmacol, 64, 1741-50.
dermocole neoplasia type 2B with a RET proto-oncogene
A883F mutation displays a more indolent form of medullary
thyroid carcinoma compared with a RET M918T mutation.
Thyroid, 21, 189-92.
phosphorylational functions for multidrug transporter
of 8F-FDG PET/CT in well differentiated thyroid carcinoma
with high serum antithyroglobulin antibody. J Med Assoc Thai, 94, 1238-44.
sequence diversity and haplotype structure in the human
ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenet genomics, 13, 481-94.
advanced thyroid cancer: a systematic review. Drugs, 72, 67-85.
Li Y, Yan PW, Huang XE, Li CG (2011). MDR1 gene C3435T
polymorphism is associated with clinical outcomes in
gastric cancer patients treated with postoperative adjuvant
genes contributing to metastasis in a mouse model of thyroid
between common 3435 C>T variants of the multi-drug resistance [MDR1 (ABCB1)] gene and abdominal aortic
Morari EC, Marcello MA, Guilhen AC, et al (2011). Use of
sodium iodide symporter expression in differentiated thyroid
carcinomas. Clin Endocrinol (Oxf), 75, 247-54.
for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg, 34, 2589-94.
Moura MM, Cavaco BM, Pinto AE et al (2011). High prevalence of RAS mutations in RET-negative sporadic medullary
of paclitaxel in ovarian cancer patients and genetic
differentiation and cell proliferation in hepatocellular
implication of hot spot BRAF mutation, V599E, in papillary
(MDR1) polymorphisms correlate with imatinib response in
with clinical T1 and T2 well-differentiated thyroid cancer. Surgery, 150, 1242-9.
frequency of 677 C>T polymorphism in the MTTHFR gene
in differentiated thyroid carcinoma. Genetic Testing and
Molecular Biomarkers, 16, 780-4.
C3435T increase the risk of leukemia: evidence from 10
case-control studies, Leuk Lymphoma, 53, 1183-7.
treatment and survival of patients with vertebral metastases
from thyroid carcinoma. Thyroid, 22, 125-30.
an MDR1 gene (C3435T) polymorphism with acute leukemia
gastric cancer incidence with MDR1 gene polymorphism in
Sedov VM, Khmelinevskaia VA (2011). Prognosis and long-term
results of treatment of patients with differentiated thyroid
carcinoma. Vestn Khir Im I I Grek, 170, 64-7.
réseau Tuthyref. [Refractory thyroid cancers]. Presse Med, 40, 1189-98.
of MDR1 gene in tumor and serum of invasive ductal breast
polymorphism and cancer risk: a meta-analysis based on 39
case-control studies. Mol Biol Rep, 39, 7237-49.
resistance gene polymorphism in tumor and serum of invasive ductal breast
and survival of patients with differentiated thyroid
carcinoma. Mol Oncol, 12, 247-54.
chromosomal rearrangements in papillary thyroid cancer
tissues: investigations at the molecular and microscopic
levels. J Physiol Pharmacol, 60, 47-55.
radioiodine therapy in differentiated thyroid cancer
subjects with elevated serum thyroglobulin and negative
whole body scan using 131I with emphasize on the thallium

DOI:http://dx.doi.org/10.7314/APJCP.2013.14.5.3213

Multidrug Resistance Gene SNP and Differentiation Thyroid Cancer